Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Практическое применение нестероидных противовоспалительных препаратов при головных болях: обзор клинических и научных данных
Практическое применение нестероидных противовоспалительных препаратов при головных болях: обзор клинических и научных данных
Сергеев А.В. Практическое применение нестероидных противовоспалительных препаратов при головных болях: обзор клинических и научных данных. Consilium Medicum. 2018; 20 (9): 39–46. DOI: 10.26442/2075-1753_2018.9.39-46
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В неврологической практике нестероидные противовоспалительные препараты (НПВП) широко используются в терапии скелетно-мышечных вертеброгенных болевых синдромов. В то же время отмечаются сложности в определении необходимости и точек эффективного применения НПВП при разных формах головных болей, особенно при мигрени. Современные экспериментальные данные показывают, что обезболивающий эффект НПВП связан не только с периферической аналгезией, но и с действием на уровне заднего рога спинного мозга, нейронов ядра тройничного нерва. Эти механизмы могут объяснять эффективность НПВП при мигрени. В обзоре обсуждается место НПВП при различных головных болях, преимущества по профилю эффективность/безопасность быстродействующих форм НПВП, стратифицированный подход к обезболиванию.
Ключевые слова: головная боль, нестероидные противовоспалительные препараты, мигрень, головная боль напряжения, цервикогенная головная боль, лорноксикам, быстродействующие формы нестероидных противовоспалительных препаратов.
Key words: cephalgia, non-steroid anti-inflammatory drugs, migraine, tension headache, cervicogenic headache, lornoxicam, fast-acting non-steroid anti-inflammatory drugs.
Ключевые слова: головная боль, нестероидные противовоспалительные препараты, мигрень, головная боль напряжения, цервикогенная головная боль, лорноксикам, быстродействующие формы нестероидных противовоспалительных препаратов.
________________________________________________
Key words: cephalgia, non-steroid anti-inflammatory drugs, migraine, tension headache, cervicogenic headache, lornoxicam, fast-acting non-steroid anti-inflammatory drugs.
Полный текст
Список литературы
1. Atchison JW, Herndon CM, Rusie E. NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. J Manag Care Spec Pharm 2013; 19 (9 Suppl. A): 1–19.
2. WHO Normative Guidelines on Pain Management. 2007. http: //www.who.int/medicines/areas/quality_safety/delphi_study_pain_guidelines
5. Tepper SJ, Dahlöf CG, Dowson A et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004; 44 (9): 856–64.
6. Acute migraine treatment in emergency settings. Comparative Effectiveness Review Summary Guides for Clinicians. Agency for Healthcare Research and Quality. www.ncbi.nlm.nih.gov/books/NBK164542/ (Accessed on November 25, 2013)/
7. Evers S, Afra J, Frese A et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 2009; 16 (9): 968–81.
8. Осипова В.В., Филатова Е.Г., Артеменко А.Р. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Журн. неврологии и психиатрии им. С.С.Корсакова. Спецвыпуски. 2017; 117 (1): 28–42. / Osipova V.V., Filatova E.G., Artemenko A.R. i dr. Diagnostika i lechenie migreni: rekomendacii rossijskih ekspertov. Zhurn. nevrologii i psihiatrii im. S.S.Korsakova. Specvypuski. 2017; 117 (1): 28–42. [in Russian]
9. Сергеев А.В. Доказательная терапия приступа мигрени. Consilium Medicum. Неврология и Ревматология (Прил.). 2015; 1: 34–7. / Sergeev A.V. Evidence-based treatment of a migraine attack. Consilium Medicum. Neurology and Rheumatology (Suppl.). 2015; 1: 34–7. [in Russian]
10. Colman I, Friedman BW, Brown MD et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336: 359.
11. Lim SS, Vos T, Flaxman AD et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–96.
12. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008; 7: 354.
13. Осипова В.В. Головная боль напряжения. Практическое руководство. М., 2009. / Osipova V.V. Golovnaya bol napryazheniya. Prakticheskoe rukovodstvo. M., 2009. [in Russian]
14. Сергеев А.В. Лечение головной боли напряжения: от старых мифов к современной концепции. РМЖ. 2015; 12: 668–74. / Sergeev A.V. Lechenie golovnoj boli napryazheniya: ot staryh mifov k sovremennoj koncepcii. RMZh. 2015; 12: 668–74. [in Russian]
15. Bendtsen L, Evers S, Linde M et al. EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur J Neurol 2010; 17: 1318.
16. Lampl C, Rudolph M, Deligianni CI, Mitsikostas DD. Neck pain in episodic migraine: premonitory symptom or part of the attack? J Headache Pain 2015; 16: 80.
17. Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009; 8: 959.
18. Табеева Т.Г. Сергеев А.В. Цервикогенная головная боль: патофизиология, клиника, подходы к терапии. Неврология, нейропсихиатрия, психосоматика. 2010; 2 (2): 19–26. / Tabeeva T.G. Sergeev A.V. Cervikogennaya golovnaya bol: patofiziologiya, klinika, podhody k terapii. Nevrologiya, nejropsihiatriya, psihosomatika. 2010; 2 (2): 19–26. [in Russian]
19. Lord SM, Barnsley L, Wallis BJ, Bogduk N. Third occipital nerve headache: a prevalence study. J Neurol Neurosurg Psychiatry 1994; 57: 1187.
20. Aprill C, Axinn MJ, Bogduk N. Occipital headaches stemming from the lateral atlanto-axial (C1-2) joint. Cephalalgia 2002; 22: 15.
21. Barnsley L, Lord S, Bogduk N. Comparative local anaesthetic blocks in the diagnosis of cervical zygapophysial joint pain. Pain 1993; 55: 99.
22. Lipton RB, Scher AI, Steiner TJ et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003; 60: 441–8.
23. Baraldi C, Pellesi L, Guerzoni S et al. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. J Headache Pain 2017; 18 (1): 71.
24. Pardutz A, Schoenen J. NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals (Basel) 2010; 3 (6): 1966–87.
25. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs differences and similarities. N Engl J Med 1991; 324 (24): 1716–25.
26. Hardman JG, Limbird LE, Gilman AG. Insel PA Analgesic-antipyretics and antiinflammatory agents and drug employed in the treatment of gout. In Goodman and Gilman's: The Pharmacological Basis for Therapeutics, 9th ed.; McGraw-Hill: New York, NY, USA, 1996; p. 617–57.
27. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9–43.
28. Melo-Carrillo A, Strassman AM, Nir R et al. Stratton and Rami Burstein. Fremanezumab – A Humanized Monoclonal Anti-CGRP Antibody – Inhibits Thinly Myelinated (Ad) But Not Unmyelinated (C) Meningeal Nociceptors. J Neurosci 2017; 37 (44): 10587–96.
29. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neurosci 1999; 89: 901–7.
30. Zhang XC, Kainz V, Jakubowski M et al. Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci Lett 2009; 452: 33–6.
31. Ellrich, J, Schepelmann K, Pawlak M, Messlinger K. Acetylsalicylic acid inhibits meningeal nociception in rat. Pain 1999; 81: 7–14.
32. Levy D, Zhang XC, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: Inhibition by naproxen. Eur J Neurosci 2008; 27: 917–22.
33. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic-acid block neurogenic plasma-protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165: 251–8.
34. Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic-acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal-cord in the cat. Headache 1993; 33: 541–4.
35. Tassorelli C, Greco R, Armentero MT et al. A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: Effects of nitroglycerin. Int Rev Neurobiol 2007; 82: 373–82.
36. Pardutz A, Szatmari E, Vecsei L, Schoenen J. Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan. Cephalalgia 2004; 24: 439–45.
37. Varga H, Pardutz A, Vamos E et al. Cox-2 inhibitor attenuates NO-induced nNOS in rat caudal trigeminal nucleus. Headache 2007; 47: 1319–25.
38. Yang GY, Lee MK, Bae YC, Ahn DK. Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 589–95.
39. Breder CD, Smith WL, Raz A et al. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol 1992; 322: 409–38.
40. Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995; 355: 296–315.
41. Shin MC, Jang MH, Chang HK et al. Modulation of cyclooxygenase-2 on glycine- and glutamate-induced ion currents in rat periaqueductal gray neurons. Brain Res Bull 2003; 59: 251–6.
42. Vaughan CW. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones. Br J Pharmacol 1998; 123: 1479–81.
43. Leith JL, Wilson AW, Donaldson LF, Lumb BM. Cyclooxygenase-1-derived prostaglandins in the periaqueductal gray differentially control C- vs. A-fiber-evoked spinal nociception. J Neurosci 2007; 27: 11296–305.
44. Koistinaho J, Chan PH. Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 2000; 25: 645–51.
45. Miettinen S, Fusco FR, Yrjanheikki J et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA 1997; 94: 6500–5.
46. Yokota C, Inoue H, Kuge Y et al. Cyclooxygenase-2 expression associated with spreading depression in a primate model. J Cereb Blood Flow Metab 2003; 23: 395–8.
47. Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51: 639–57.
48. Hillstrom C, Jakobsson JG. Lornoxicam: pharmacology and usefulness to treat acute postoperative and musculoskeletal pain a narrative review. Expert Opin Pharmacother 2013; 14 (12): 1679–94.
49. Ксефокам Рапид – официальная инструкция по применению. http: //grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fa943cbf-5cd8-4e53-8923-2ef77ae5f4b4&t= / Ksefokam Rapid – oficialnaya instrukciya po primeneniyu. http: //grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fa943cbf-5cd8-4e53-8923-2ef77ae5f4b4&t= [in Russian]
2. WHO Normative Guidelines on Pain Management. 2007. http: //www.who.int/medicines/areas/quality_safety/delphi_study_pain_guidelines
3. Lipton RB, Stewart WF, Stone AM et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000; 284: 2599.
4. The 3rd edition of the International Classification of Headache Disorders (ICHD-3). Cephalalgia 2018; 38 (1) 1–211.
5. Tepper SJ, Dahlöf CG, Dowson A et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004; 44 (9): 856–64.
6. Acute migraine treatment in emergency settings. Comparative Effectiveness Review Summary Guides for Clinicians. Agency for Healthcare Research and Quality. www.ncbi.nlm.nih.gov/books/NBK164542/ (Accessed on November 25, 2013)/
7. Evers S, Afra J, Frese A et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 2009; 16 (9): 968–81.
8. Osipova V.V., Filatova E.G., Artemenko A.R. i dr. Diagnostika i lechenie migreni: rekomendacii rossijskih ekspertov. Zhurn. nevrologii i psihiatrii im. S.S.Korsakova. Specvypuski. 2017; 117 (1): 28–42. [in Russian]
9. Sergeev A.V. Evidence-based treatment of a migraine attack. Consilium Medicum. Neurology and Rheumatology (Suppl.). 2015; 1: 34–7. [in Russian]
10. Colman I, Friedman BW, Brown MD et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336: 359.
11. Lim SS, Vos T, Flaxman AD et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–96.
12. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008; 7: 354.
13. Osipova V.V. Golovnaya bol napryazheniya. Prakticheskoe rukovodstvo. M., 2009. [in Russian]
14. Sergeev A.V. Lechenie golovnoj boli napryazheniya: ot staryh mifov k sovremennoj koncepcii. RMZh. 2015; 12: 668–74. [in Russian]
15. Bendtsen L, Evers S, Linde M et al. EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur J Neurol 2010; 17: 1318.
16. Lampl C, Rudolph M, Deligianni CI, Mitsikostas DD. Neck pain in episodic migraine: premonitory symptom or part of the attack? J Headache Pain 2015; 16: 80.
17. Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009; 8: 959.
18. Tabeeva T.G. Sergeev A.V. Cervikogennaya golovnaya bol: patofiziologiya, klinika, podhody k terapii. Nevrologiya, nejropsihiatriya, psihosomatika. 2010; 2 (2): 19–26. [in Russian]
19. Lord SM, Barnsley L, Wallis BJ, Bogduk N. Third occipital nerve headache: a prevalence study. J Neurol Neurosurg Psychiatry 1994; 57: 1187.
20. Aprill C, Axinn MJ, Bogduk N. Occipital headaches stemming from the lateral atlanto-axial (C1-2) joint. Cephalalgia 2002; 22: 15.
21. Barnsley L, Lord S, Bogduk N. Comparative local anaesthetic blocks in the diagnosis of cervical zygapophysial joint pain. Pain 1993; 55: 99.
22. Lipton RB, Scher AI, Steiner TJ et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003; 60: 441–8.
23. Baraldi C, Pellesi L, Guerzoni S et al. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. J Headache Pain 2017; 18 (1): 71.
24. Pardutz A, Schoenen J. NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals (Basel) 2010; 3 (6): 1966–87.
25. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs differences and similarities. N Engl J Med 1991; 324 (24): 1716–25.
26. Hardman JG, Limbird LE, Gilman AG. Insel PA Analgesic-antipyretics and antiinflammatory agents and drug employed in the treatment of gout. In Goodman and Gilman's: The Pharmacological Basis for Therapeutics, 9th ed.; McGraw-Hill: New York, NY, USA, 1996; p. 617–57.
27. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9–43.
28. Melo-Carrillo A, Strassman AM, Nir R et al. Stratton and Rami Burstein. Fremanezumab – A Humanized Monoclonal Anti-CGRP Antibody – Inhibits Thinly Myelinated (Ad) But Not Unmyelinated (C) Meningeal Nociceptors. J Neurosci 2017; 37 (44): 10587–96.
29. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neurosci 1999; 89: 901–7.
30. Zhang XC, Kainz V, Jakubowski M et al. Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci Lett 2009; 452: 33–6.
31. Ellrich, J, Schepelmann K, Pawlak M, Messlinger K. Acetylsalicylic acid inhibits meningeal nociception in rat. Pain 1999; 81: 7–14.
32. Levy D, Zhang XC, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: Inhibition by naproxen. Eur J Neurosci 2008; 27: 917–22.
33. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic-acid block neurogenic plasma-protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165: 251–8.
34. Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic-acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal-cord in the cat. Headache 1993; 33: 541–4.
35. Tassorelli C, Greco R, Armentero MT et al. A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: Effects of nitroglycerin. Int Rev Neurobiol 2007; 82: 373–82.
36. Pardutz A, Szatmari E, Vecsei L, Schoenen J. Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan. Cephalalgia 2004; 24: 439–45.
37. Varga H, Pardutz A, Vamos E et al. Cox-2 inhibitor attenuates NO-induced nNOS in rat caudal trigeminal nucleus. Headache 2007; 47: 1319–25.
38. Yang GY, Lee MK, Bae YC, Ahn DK. Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 589–95.
39. Breder CD, Smith WL, Raz A et al. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol 1992; 322: 409–38.
40. Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995; 355: 296–315.
41. Shin MC, Jang MH, Chang HK et al. Modulation of cyclooxygenase-2 on glycine- and glutamate-induced ion currents in rat periaqueductal gray neurons. Brain Res Bull 2003; 59: 251–6.
42. Vaughan CW. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones. Br J Pharmacol 1998; 123: 1479–81.
43. Leith JL, Wilson AW, Donaldson LF, Lumb BM. Cyclooxygenase-1-derived prostaglandins in the periaqueductal gray differentially control C- vs. A-fiber-evoked spinal nociception. J Neurosci 2007; 27: 11296–305.
44. Koistinaho J, Chan PH. Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 2000; 25: 645–51.
45. Miettinen S, Fusco FR, Yrjanheikki J et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA 1997; 94: 6500–5.
46. Yokota C, Inoue H, Kuge Y et al. Cyclooxygenase-2 expression associated with spreading depression in a primate model. J Cereb Blood Flow Metab 2003; 23: 395–8.
47. Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51: 639–57.
48. Hillstrom C, Jakobsson JG. Lornoxicam: pharmacology and usefulness to treat acute postoperative and musculoskeletal pain a narrative review. Expert Opin Pharmacother 2013; 14 (12): 1679–94.
49. Ksefokam Rapid – oficialnaya instrukciya po primeneniyu. http: //grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fa943cbf-5cd8-4e53-8923-2ef77ae5f4b4&t= [in Russian]
2. WHO Normative Guidelines on Pain Management. 2007. http: //www.who.int/medicines/areas/quality_safety/delphi_study_pain_guidelines
3. Lipton RB, Stewart WF, Stone AM et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000; 284: 2599.
4. The 3rd edition of the International Classification of Headache Disorders (ICHD-3). Cephalalgia 2018; 38 (1) 1–211. 5. Tepper SJ, Dahlöf CG, Dowson A et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004; 44 (9): 856–64.
6. Acute migraine treatment in emergency settings. Comparative Effectiveness Review Summary Guides for Clinicians. Agency for Healthcare Research and Quality. www.ncbi.nlm.nih.gov/books/NBK164542/ (Accessed on November 25, 2013)/
7. Evers S, Afra J, Frese A et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 2009; 16 (9): 968–81.
8. Осипова В.В., Филатова Е.Г., Артеменко А.Р. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Журн. неврологии и психиатрии им. С.С.Корсакова. Спецвыпуски. 2017; 117 (1): 28–42. / Osipova V.V., Filatova E.G., Artemenko A.R. i dr. Diagnostika i lechenie migreni: rekomendacii rossijskih ekspertov. Zhurn. nevrologii i psihiatrii im. S.S.Korsakova. Specvypuski. 2017; 117 (1): 28–42. [in Russian]
9. Сергеев А.В. Доказательная терапия приступа мигрени. Consilium Medicum. Неврология и Ревматология (Прил.). 2015; 1: 34–7. / Sergeev A.V. Evidence-based treatment of a migraine attack. Consilium Medicum. Neurology and Rheumatology (Suppl.). 2015; 1: 34–7. [in Russian]
10. Colman I, Friedman BW, Brown MD et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336: 359.
11. Lim SS, Vos T, Flaxman AD et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–96.
12. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008; 7: 354.
13. Осипова В.В. Головная боль напряжения. Практическое руководство. М., 2009. / Osipova V.V. Golovnaya bol napryazheniya. Prakticheskoe rukovodstvo. M., 2009. [in Russian]
14. Сергеев А.В. Лечение головной боли напряжения: от старых мифов к современной концепции. РМЖ. 2015; 12: 668–74. / Sergeev A.V. Lechenie golovnoj boli napryazheniya: ot staryh mifov k sovremennoj koncepcii. RMZh. 2015; 12: 668–74. [in Russian]
15. Bendtsen L, Evers S, Linde M et al. EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur J Neurol 2010; 17: 1318.
16. Lampl C, Rudolph M, Deligianni CI, Mitsikostas DD. Neck pain in episodic migraine: premonitory symptom or part of the attack? J Headache Pain 2015; 16: 80.
17. Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009; 8: 959.
18. Табеева Т.Г. Сергеев А.В. Цервикогенная головная боль: патофизиология, клиника, подходы к терапии. Неврология, нейропсихиатрия, психосоматика. 2010; 2 (2): 19–26. / Tabeeva T.G. Sergeev A.V. Cervikogennaya golovnaya bol: patofiziologiya, klinika, podhody k terapii. Nevrologiya, nejropsihiatriya, psihosomatika. 2010; 2 (2): 19–26. [in Russian]
19. Lord SM, Barnsley L, Wallis BJ, Bogduk N. Third occipital nerve headache: a prevalence study. J Neurol Neurosurg Psychiatry 1994; 57: 1187.
20. Aprill C, Axinn MJ, Bogduk N. Occipital headaches stemming from the lateral atlanto-axial (C1-2) joint. Cephalalgia 2002; 22: 15.
21. Barnsley L, Lord S, Bogduk N. Comparative local anaesthetic blocks in the diagnosis of cervical zygapophysial joint pain. Pain 1993; 55: 99.
22. Lipton RB, Scher AI, Steiner TJ et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003; 60: 441–8.
23. Baraldi C, Pellesi L, Guerzoni S et al. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. J Headache Pain 2017; 18 (1): 71.
24. Pardutz A, Schoenen J. NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals (Basel) 2010; 3 (6): 1966–87.
25. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs differences and similarities. N Engl J Med 1991; 324 (24): 1716–25.
26. Hardman JG, Limbird LE, Gilman AG. Insel PA Analgesic-antipyretics and antiinflammatory agents and drug employed in the treatment of gout. In Goodman and Gilman's: The Pharmacological Basis for Therapeutics, 9th ed.; McGraw-Hill: New York, NY, USA, 1996; p. 617–57.
27. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9–43.
28. Melo-Carrillo A, Strassman AM, Nir R et al. Stratton and Rami Burstein. Fremanezumab – A Humanized Monoclonal Anti-CGRP Antibody – Inhibits Thinly Myelinated (Ad) But Not Unmyelinated (C) Meningeal Nociceptors. J Neurosci 2017; 37 (44): 10587–96.
29. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neurosci 1999; 89: 901–7.
30. Zhang XC, Kainz V, Jakubowski M et al. Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci Lett 2009; 452: 33–6.
31. Ellrich, J, Schepelmann K, Pawlak M, Messlinger K. Acetylsalicylic acid inhibits meningeal nociception in rat. Pain 1999; 81: 7–14.
32. Levy D, Zhang XC, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: Inhibition by naproxen. Eur J Neurosci 2008; 27: 917–22.
33. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic-acid block neurogenic plasma-protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165: 251–8.
34. Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic-acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal-cord in the cat. Headache 1993; 33: 541–4.
35. Tassorelli C, Greco R, Armentero MT et al. A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: Effects of nitroglycerin. Int Rev Neurobiol 2007; 82: 373–82.
36. Pardutz A, Szatmari E, Vecsei L, Schoenen J. Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan. Cephalalgia 2004; 24: 439–45.
37. Varga H, Pardutz A, Vamos E et al. Cox-2 inhibitor attenuates NO-induced nNOS in rat caudal trigeminal nucleus. Headache 2007; 47: 1319–25.
38. Yang GY, Lee MK, Bae YC, Ahn DK. Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 589–95.
39. Breder CD, Smith WL, Raz A et al. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol 1992; 322: 409–38.
40. Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995; 355: 296–315.
41. Shin MC, Jang MH, Chang HK et al. Modulation of cyclooxygenase-2 on glycine- and glutamate-induced ion currents in rat periaqueductal gray neurons. Brain Res Bull 2003; 59: 251–6.
42. Vaughan CW. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones. Br J Pharmacol 1998; 123: 1479–81.
43. Leith JL, Wilson AW, Donaldson LF, Lumb BM. Cyclooxygenase-1-derived prostaglandins in the periaqueductal gray differentially control C- vs. A-fiber-evoked spinal nociception. J Neurosci 2007; 27: 11296–305.
44. Koistinaho J, Chan PH. Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 2000; 25: 645–51.
45. Miettinen S, Fusco FR, Yrjanheikki J et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA 1997; 94: 6500–5.
46. Yokota C, Inoue H, Kuge Y et al. Cyclooxygenase-2 expression associated with spreading depression in a primate model. J Cereb Blood Flow Metab 2003; 23: 395–8.
47. Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51: 639–57.
48. Hillstrom C, Jakobsson JG. Lornoxicam: pharmacology and usefulness to treat acute postoperative and musculoskeletal pain a narrative review. Expert Opin Pharmacother 2013; 14 (12): 1679–94.
49. Ксефокам Рапид – официальная инструкция по применению. http: //grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fa943cbf-5cd8-4e53-8923-2ef77ae5f4b4&t= / Ksefokam Rapid – oficialnaya instrukciya po primeneniyu. http: //grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fa943cbf-5cd8-4e53-8923-2ef77ae5f4b4&t= [in Russian]
________________________________________________
2. WHO Normative Guidelines on Pain Management. 2007. http: //www.who.int/medicines/areas/quality_safety/delphi_study_pain_guidelines
3. Lipton RB, Stewart WF, Stone AM et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000; 284: 2599.
4. The 3rd edition of the International Classification of Headache Disorders (ICHD-3). Cephalalgia 2018; 38 (1) 1–211.
5. Tepper SJ, Dahlöf CG, Dowson A et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004; 44 (9): 856–64.
6. Acute migraine treatment in emergency settings. Comparative Effectiveness Review Summary Guides for Clinicians. Agency for Healthcare Research and Quality. www.ncbi.nlm.nih.gov/books/NBK164542/ (Accessed on November 25, 2013)/
7. Evers S, Afra J, Frese A et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 2009; 16 (9): 968–81.
8. Osipova V.V., Filatova E.G., Artemenko A.R. i dr. Diagnostika i lechenie migreni: rekomendacii rossijskih ekspertov. Zhurn. nevrologii i psihiatrii im. S.S.Korsakova. Specvypuski. 2017; 117 (1): 28–42. [in Russian]
9. Sergeev A.V. Evidence-based treatment of a migraine attack. Consilium Medicum. Neurology and Rheumatology (Suppl.). 2015; 1: 34–7. [in Russian]
10. Colman I, Friedman BW, Brown MD et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336: 359.
11. Lim SS, Vos T, Flaxman AD et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–96.
12. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008; 7: 354.
13. Osipova V.V. Golovnaya bol napryazheniya. Prakticheskoe rukovodstvo. M., 2009. [in Russian]
14. Sergeev A.V. Lechenie golovnoj boli napryazheniya: ot staryh mifov k sovremennoj koncepcii. RMZh. 2015; 12: 668–74. [in Russian]
15. Bendtsen L, Evers S, Linde M et al. EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur J Neurol 2010; 17: 1318.
16. Lampl C, Rudolph M, Deligianni CI, Mitsikostas DD. Neck pain in episodic migraine: premonitory symptom or part of the attack? J Headache Pain 2015; 16: 80.
17. Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009; 8: 959.
18. Tabeeva T.G. Sergeev A.V. Cervikogennaya golovnaya bol: patofiziologiya, klinika, podhody k terapii. Nevrologiya, nejropsihiatriya, psihosomatika. 2010; 2 (2): 19–26. [in Russian]
19. Lord SM, Barnsley L, Wallis BJ, Bogduk N. Third occipital nerve headache: a prevalence study. J Neurol Neurosurg Psychiatry 1994; 57: 1187.
20. Aprill C, Axinn MJ, Bogduk N. Occipital headaches stemming from the lateral atlanto-axial (C1-2) joint. Cephalalgia 2002; 22: 15.
21. Barnsley L, Lord S, Bogduk N. Comparative local anaesthetic blocks in the diagnosis of cervical zygapophysial joint pain. Pain 1993; 55: 99.
22. Lipton RB, Scher AI, Steiner TJ et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003; 60: 441–8.
23. Baraldi C, Pellesi L, Guerzoni S et al. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. J Headache Pain 2017; 18 (1): 71.
24. Pardutz A, Schoenen J. NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals (Basel) 2010; 3 (6): 1966–87.
25. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs differences and similarities. N Engl J Med 1991; 324 (24): 1716–25.
26. Hardman JG, Limbird LE, Gilman AG. Insel PA Analgesic-antipyretics and antiinflammatory agents and drug employed in the treatment of gout. In Goodman and Gilman's: The Pharmacological Basis for Therapeutics, 9th ed.; McGraw-Hill: New York, NY, USA, 1996; p. 617–57.
27. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9–43.
28. Melo-Carrillo A, Strassman AM, Nir R et al. Stratton and Rami Burstein. Fremanezumab – A Humanized Monoclonal Anti-CGRP Antibody – Inhibits Thinly Myelinated (Ad) But Not Unmyelinated (C) Meningeal Nociceptors. J Neurosci 2017; 37 (44): 10587–96.
29. Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neurosci 1999; 89: 901–7.
30. Zhang XC, Kainz V, Jakubowski M et al. Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci Lett 2009; 452: 33–6.
31. Ellrich, J, Schepelmann K, Pawlak M, Messlinger K. Acetylsalicylic acid inhibits meningeal nociception in rat. Pain 1999; 81: 7–14.
32. Levy D, Zhang XC, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: Inhibition by naproxen. Eur J Neurosci 2008; 27: 917–22.
33. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic-acid block neurogenic plasma-protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165: 251–8.
34. Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic-acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal-cord in the cat. Headache 1993; 33: 541–4.
35. Tassorelli C, Greco R, Armentero MT et al. A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: Effects of nitroglycerin. Int Rev Neurobiol 2007; 82: 373–82.
36. Pardutz A, Szatmari E, Vecsei L, Schoenen J. Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan. Cephalalgia 2004; 24: 439–45.
37. Varga H, Pardutz A, Vamos E et al. Cox-2 inhibitor attenuates NO-induced nNOS in rat caudal trigeminal nucleus. Headache 2007; 47: 1319–25.
38. Yang GY, Lee MK, Bae YC, Ahn DK. Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 589–95.
39. Breder CD, Smith WL, Raz A et al. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol 1992; 322: 409–38.
40. Breder CD, Dewitt D, Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995; 355: 296–315.
41. Shin MC, Jang MH, Chang HK et al. Modulation of cyclooxygenase-2 on glycine- and glutamate-induced ion currents in rat periaqueductal gray neurons. Brain Res Bull 2003; 59: 251–6.
42. Vaughan CW. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones. Br J Pharmacol 1998; 123: 1479–81.
43. Leith JL, Wilson AW, Donaldson LF, Lumb BM. Cyclooxygenase-1-derived prostaglandins in the periaqueductal gray differentially control C- vs. A-fiber-evoked spinal nociception. J Neurosci 2007; 27: 11296–305.
44. Koistinaho J, Chan PH. Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 2000; 25: 645–51.
45. Miettinen S, Fusco FR, Yrjanheikki J et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA 1997; 94: 6500–5.
46. Yokota C, Inoue H, Kuge Y et al. Cyclooxygenase-2 expression associated with spreading depression in a primate model. J Cereb Blood Flow Metab 2003; 23: 395–8.
47. Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51: 639–57.
48. Hillstrom C, Jakobsson JG. Lornoxicam: pharmacology and usefulness to treat acute postoperative and musculoskeletal pain a narrative review. Expert Opin Pharmacother 2013; 14 (12): 1679–94.
49. Ksefokam Rapid – oficialnaya instrukciya po primeneniyu. http: //grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fa943cbf-5cd8-4e53-8923-2ef77ae5f4b4&t= [in Russian]
Авторы
А.В.Сергеев
1 ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М.Сеченова, 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2 Клиника нервных болезней им. А.Я.Кожевникова. 119021, Россия, Москва, ул. Россолимо, д. 11, стр. 1
sergeev.neuro@gmail.com
1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2 A.Ya.Kozhevnikov Clinic for Nervous Diseases. 119021, Russian Federation, Moscow, ul. Rossolimo, d. 11, str. 1
sergeev.neuro@gmail.com
1 ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М.Сеченова, 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2 Клиника нервных болезней им. А.Я.Кожевникова. 119021, Россия, Москва, ул. Россолимо, д. 11, стр. 1
sergeev.neuro@gmail.com
________________________________________________
1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2 A.Ya.Kozhevnikov Clinic for Nervous Diseases. 119021, Russian Federation, Moscow, ul. Rossolimo, d. 11, str. 1
sergeev.neuro@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.